Jae Park, MD, Memorial Sloan Kettering Cancer Center

Articles

ASH Updates for CAR T-Cell Therapy in Acute Lymphoblastic Leukemia

March 4th 2021

Evolving Field of Acute Lymphoblastic Leukemia

March 4th 2021

Investigational CAR T-Cell Therapy in Acute Lymphoblastic Leukemia

February 25th 2021

CAR T-Cell Therapy Use in Second Line Acute Lymphoblastic Leukemia

February 25th 2021

CAR T-Cell Therapy After First Relapse of Acute Lymphoblastic Leukemia

February 18th 2021

Approach to Managing Relapsed Acute Lymphoblastic Leukemia

February 18th 2021

Role of Transplant in Older Adults With Acute Lymphoblastic Leukemia

February 11th 2021

Managing MRD-Negative Acute Lymphoblastic Leukemia

February 11th 2021

Managing MRD-Positive Acute Lymphoblastic Leukemia

February 4th 2021

Treatment of Acute Lymphoblastic Leukemia in the Community Setting

February 4th 2021

Role of MRD Testing in Acute Lymphoblastic Leukemia

January 28th 2021

Treating Older Adult Patients With Philadelphia Chromosome-Negative ALL

January 28th 2021

Treating Young Adult Patients With Philadelphia Chromosome-Negative ALL

January 21st 2021

Treating Older Adult Patients With Philadelphia Chromosome-Positive ALL

January 13th 2021

Treating Young Adult Patients With Philadelphia Chromosome–Positive ALL

January 13th 2021

Prognostic Factors Which Impact ALL Management

January 13th 2021

Advice for Community Oncologists on Treating HCL

June 30th 2020

Treatments for Relapsed/Refractory HCL in Pipeline

June 30th 2020

The Role of CD22-targeted Immunotoxins in HCL

June 30th 2020

Landscape Change in the Treatment of Relapsed/Refractory HCL

June 30th 2020